[HTML] nature.com

[HTML][HTML] Overcoming the challenges associated with CD3+ T-cell redirection in cancer

A Singh, S Dees, IS Grewal - British journal of cancer, 2021 - nature.com
The development of bispecific antibodies that redirect the cytotoxic activity of CD3+ T cells to
tumours is a promising immunotherapeutic strategy for the treatment of haematological …
被引用次数：70 相关文章
[PDF] academia.edu

[PDF][PDF] Overcoming the challenges associated with CD3+ T-cell redirection in cancer

A Singh, S Dees, IS Grewal - 2021 - academia.edu
BACKGROUND The development of antibody therapeutics has transformed the field of
cancer immunotherapy. The first successful monoclonal antibody (mAb) therapy in oncology …
[HTML] nih.gov

[HTML][HTML] Overcoming the challenges associated with CD3+ T-cell redirection in cancer

A Singh, S Dees, IS Grewal - British Journal of Cancer, 2021 - ncbi.nlm.nih.gov
The development of bispecific antibodies that redirect the cytotoxic activity of CD3+ T cells to
tumours is a promising immunotherapeutic strategy for the treatment of haematological …

Overcoming the challenges associated with CD3+ T-cell redirection in cancer.

A Singh, S Dees, IS Grewal - British Journal of Cancer, 2021 - europepmc.org
The development of bispecific antibodies that redirect the cytotoxic activity of CD3+ T cells to
tumours is a promising immunotherapeutic strategy for the treatment of haematological …

Overcoming the challenges associated with CD3+ T-cell redirection in cancer

A Singh, S Dees, IS Grewal - British journal of cancer, 2021 - pubmed.ncbi.nlm.nih.gov
The development of bispecific antibodies that redirect the cytotoxic activity of CD3+ T cells to
tumours is a promising immunotherapeutic strategy for the treatment of haematological …